Medpace (NASDAQ:MEDP) Rating Increased to Hold at Leerink Partnrs

Medpace (NASDAQ:MEDP) was upgraded by stock analysts at Leerink Partnrs to a “hold” rating in a report issued on Monday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Robert W. Baird boosted their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partners began coverage on shares of Medpace in a research note on Monday. They set a “market perform” rating and a $330.00 price target for the company. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Trading Down 1.8 %

NASDAQ:MEDP opened at $324.51 on Monday. Medpace has a 12 month low of $302.01 and a 12 month high of $459.77. The stock has a market capitalization of $9.89 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 3.81 and a beta of 1.47. The firm has a fifty day simple moving average of $337.16 and a two-hundred day simple moving average of $339.57.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities analysts predict that Medpace will post 12.29 earnings per share for the current fiscal year.

Institutional Trading of Medpace

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Medpace by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company’s stock worth $854,087,000 after purchasing an additional 25,704 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Medpace by 91.8% in the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company’s stock worth $360,387,000 after buying an additional 519,186 shares during the last quarter. Wasatch Advisors LP boosted its stake in shares of Medpace by 3.1% in the 4th quarter. Wasatch Advisors LP now owns 936,842 shares of the company’s stock worth $311,247,000 after buying an additional 28,161 shares during the last quarter. State Street Corp grew its holdings in shares of Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after acquiring an additional 50,312 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Medpace by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 656,130 shares of the company’s stock valued at $218,031,000 after acquiring an additional 28,076 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.